Optysys™

Sector: Ocular Therapeutics / Precision Drug Delivery
Stage: Pre-commercial; patent applications filed, IP-structured, and scenario-tested across therapeutic use cases
Application Domains: Retinal and neuro-ocular disease modulation, drug delivery, sustained-release ophthalmics, post-surgical intervention

URL: www.optysys.com

Optysys™ is a modular, intraocular therapeutic platform designed to deliver precise, extended-release drug payloads directly through the optical pathway—without compromising vision, comfort, or corneal integrity.

The system operates through a discreetly positioned, non-invasive delivery insert engineered for high compatibility with ocular physiology and therapeutic flexibility.

Unlike eyedrops, injections, or punctal plugs—which suffer from poor adherence, rapid diffusion, or patient discomfort—Optysys provides a high-retention, physiology-adapted solution for targeted delivery and duration-controlled release.

Performance Metrics & Testing Highlights

Extensive design modeling and in vitro simulation have been conducted across multiple disease-use contexts and anatomical conditions. All testbed structures used inert, non-drug analog payloads to model biocompatibility and mechanical efficacy.

Performance Indicator Result

Retention Stability: >96% positional stability over 7-day active wear periods

User Visual Interference: 0% pupil or peripheral occlusion in sub-iris placement trials

Payload Capacity: Compatible with nanoliter-to-microliter scalable payload chambers

Anatomical Conformity: Form factors successfully mapped to >85% of modeled orbital geometries

Sterilization Pathways: System-compatible with autoclave, e-beam, and ethylene oxide methods

All delivery system modeling was conducted without active agents; therapeutic integration testing is planned in conjunction with licensee-directed formulation partners.

Strategic Differentiation

Optysys addresses a growing need for non-invasive, high-precision ocular drug delivery by offering:

• Anatomy-adaptive design with no vision interference

• Controlled-release delivery engineered to sustain local drug exposure over time

• Platform modularity—supporting small-molecule, biologic, or hybrid payload formats

• Surgical and non-surgical pathways, with potential applications in retina, optic nerve, and post-op compliance markets

Its unique positioning bridges the gap between traditional topical delivery and invasive procedural dosing, offering a platform adaptable to diverse clinical needs.

Commercial & Licensing Readiness

Optysys is intended for licensing to partners in ophthalmology, neuro-therapeutics, or ocular-adjacent biopharma sectors. Licensing discussions are open to:

• Drug developers seeking platform delivery for IP-protected payloads

• Ophthalmic device manufacturers interested in modular integration

• Strategic medical portfolio holders looking to expand into microdose delivery platforms

• Surgical systems firms seeking post-op compliance and healing adjuncts

Manufacturing profiles, non-clinical performance modeling, and CAD-based system designs are available under NDA for qualified licensees. All trade-secret formulation logic, release kinetics, and material selection strategies remain confidential and are protected under patent and internal protocol structures.

Licensing Engagement

Optysys is now available for confidential licensing discussion. Deployment formats may include modular OEM integration, therapeutic-specific exclusivity, or co-development structures based on payload class and market segment. Select exclusivity options are available by region or indication.

Request a private briefing through our intake portal to begin. contact@ipboardwalk.com